FW: [HepC] Anti-Hepatitis C Ribozyme Safety and Pharmacokinetics Trial Successfully Complet

[Guest guest]

-----Original Message-----From: Demastus@... [mailto:Demastus@...]Sent: Monday, September 11, 2000 6:28 PMHepCegroupsSubject: [HepC] Anti-Hepatitis C Ribozyme Safety and Pharmacokinetics Trial Successfully Complet

Anti-Hepatitis C Ribozyme Safety and Pharmacokinetics Trial Successfully CompletedBOULDER, Colo. and INDIANAPOLIS, Sept. 11 /PRNewswire/ -- Ribozyme Pharmaceuticals, Inc. (RPI) (Nasdaq: RZYM) and Eli Lilly and Company (NYSE: LLY) announced today the successful completion of a safety and pharmacokinetic study of LY466700, the Anti-Hepatitis C ribozyme compound discovered by RPI.The trial was designed to examine safety and bioavailability in patients during a 28 day dosing regimen and was not designed to determine efficacy. Preliminary results indicate that the drug was very well tolerated over a 28 day period and that its pharmacokinetic characteristics support a subcutaneous dosing regimen, a mode of administration already familiar to chronic Hepatitis C patients."In contrast to currently available Hepatitis C therapies, this new class of therapeutics has shown an exceptional safety profile thus far," said Ralph E. Christoffersen, Ph.D., President and CEO of Ribozyme Pharmaceuticals. "We are pleased with the results of this study."Data from the most recent clinical trials will be discussed at the American Association for the Study of Liver Diseases (AASLD) conference in Dallas, Texas October 26-29.Ribozymes are the product of Nobel Prize winning science and are synthetically engineered to act as "molecular scissors" capable of cleaving target RNA in a highly specific manner.Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs.RPI (www.rpi.com), located in Boulder, Colorado, is the acknowledged leader in ribozyme therapeutic development. In addition to its collaboration with Lilly for development of an anti-HCV ribozyme, RPI is partnered with Chiron Corporation for the development and commercialization of ANGIOZYME, an anti-angiogenic ribozyme designed to inhibit the growth of new blood supplies to tumors and prevent tumor growth and metastasis. ANGIOZYME is in Phase I/II clinical trials in cancer patients at the Cleveland Clinic. RPI is also partnered with an affiliate of Elan Corporation plc for development and commercialization of HERZYME, an anti-HER-2 ribozyme for treatment of breast and other cancers, through RPI's subsidiary Medizyme Pharmaceuticals Ltd.This press release contains forward-looking statements that involve risks and uncertainties, and actual events or results may differ materially. These risk factors include the outcome of future clinical trials, actions by the U.S. Food and Drug Administration, technological advances, ability to obtain rights to technology, ability to obtain and enforce patents, ability to commercialize and manufacture products and general economic conditions. These and additional risk factors are identified in RPI and Lilly Securities and Exchange Commission filings, including the Forms 10-K and 10-Q and in other SEC filings.SOURCE Ribozyme Pharmaceuticals, Inc. and Eli Lilly and Company VOTE For My List! Help us become No. 1.Check out which lists are the most POPULAR!Vote Now : <A HREF=" http://www.e4joy.com/cgi-bin/r.cgi?i=283 ">The ListDirectory</A>--- THE LIST DIRECTORY ----Jokes : Toons : Free Stuff : Motivation : InternetFind the Worlds most popular Mailing Lists:<A HREF=" http://www.e4joy.com/cgi-bin/r.cgi?i=283 ">The List Directory</A>

[Guest guest]

-----Original Message-----From: Demastus@... [mailto:Demastus@...]Sent: Monday, September 11, 2000 6:28 PMHepCegroupsSubject: [HepC] Anti-Hepatitis C Ribozyme Safety and Pharmacokinetics Trial Successfully Complet

Anti-Hepatitis C Ribozyme Safety and Pharmacokinetics Trial Successfully CompletedBOULDER, Colo. and INDIANAPOLIS, Sept. 11 /PRNewswire/ -- Ribozyme Pharmaceuticals, Inc. (RPI) (Nasdaq: RZYM) and Eli Lilly and Company (NYSE: LLY) announced today the successful completion of a safety and pharmacokinetic study of LY466700, the Anti-Hepatitis C ribozyme compound discovered by RPI.The trial was designed to examine safety and bioavailability in patients during a 28 day dosing regimen and was not designed to determine efficacy. Preliminary results indicate that the drug was very well tolerated over a 28 day period and that its pharmacokinetic characteristics support a subcutaneous dosing regimen, a mode of administration already familiar to chronic Hepatitis C patients."In contrast to currently available Hepatitis C therapies, this new class of therapeutics has shown an exceptional safety profile thus far," said Ralph E. Christoffersen, Ph.D., President and CEO of Ribozyme Pharmaceuticals. "We are pleased with the results of this study."Data from the most recent clinical trials will be discussed at the American Association for the Study of Liver Diseases (AASLD) conference in Dallas, Texas October 26-29.Ribozymes are the product of Nobel Prize winning science and are synthetically engineered to act as "molecular scissors" capable of cleaving target RNA in a highly specific manner.Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs.RPI (www.rpi.com), located in Boulder, Colorado, is the acknowledged leader in ribozyme therapeutic development. In addition to its collaboration with Lilly for development of an anti-HCV ribozyme, RPI is partnered with Chiron Corporation for the development and commercialization of ANGIOZYME, an anti-angiogenic ribozyme designed to inhibit the growth of new blood supplies to tumors and prevent tumor growth and metastasis. ANGIOZYME is in Phase I/II clinical trials in cancer patients at the Cleveland Clinic. RPI is also partnered with an affiliate of Elan Corporation plc for development and commercialization of HERZYME, an anti-HER-2 ribozyme for treatment of breast and other cancers, through RPI's subsidiary Medizyme Pharmaceuticals Ltd.This press release contains forward-looking statements that involve risks and uncertainties, and actual events or results may differ materially. These risk factors include the outcome of future clinical trials, actions by the U.S. Food and Drug Administration, technological advances, ability to obtain rights to technology, ability to obtain and enforce patents, ability to commercialize and manufacture products and general economic conditions. These and additional risk factors are identified in RPI and Lilly Securities and Exchange Commission filings, including the Forms 10-K and 10-Q and in other SEC filings.SOURCE Ribozyme Pharmaceuticals, Inc. and Eli Lilly and Company VOTE For My List! Help us become No. 1.Check out which lists are the most POPULAR!Vote Now : <A HREF=" http://www.e4joy.com/cgi-bin/r.cgi?i=283 ">The ListDirectory</A>--- THE LIST DIRECTORY ----Jokes : Toons : Free Stuff : Motivation : InternetFind the Worlds most popular Mailing Lists:<A HREF=" http://www.e4joy.com/cgi-bin/r.cgi?i=283 ">The List Directory</A>

[Guest guest]

-----Original Message-----From: Demastus@... [mailto:Demastus@...]Sent: Monday, September 11, 2000 6:28 PMHepCegroupsSubject: [HepC] Anti-Hepatitis C Ribozyme Safety and Pharmacokinetics Trial Successfully Complet

Anti-Hepatitis C Ribozyme Safety and Pharmacokinetics Trial Successfully CompletedBOULDER, Colo. and INDIANAPOLIS, Sept. 11 /PRNewswire/ -- Ribozyme Pharmaceuticals, Inc. (RPI) (Nasdaq: RZYM) and Eli Lilly and Company (NYSE: LLY) announced today the successful completion of a safety and pharmacokinetic study of LY466700, the Anti-Hepatitis C ribozyme compound discovered by RPI.The trial was designed to examine safety and bioavailability in patients during a 28 day dosing regimen and was not designed to determine efficacy. Preliminary results indicate that the drug was very well tolerated over a 28 day period and that its pharmacokinetic characteristics support a subcutaneous dosing regimen, a mode of administration already familiar to chronic Hepatitis C patients."In contrast to currently available Hepatitis C therapies, this new class of therapeutics has shown an exceptional safety profile thus far," said Ralph E. Christoffersen, Ph.D., President and CEO of Ribozyme Pharmaceuticals. "We are pleased with the results of this study."Data from the most recent clinical trials will be discussed at the American Association for the Study of Liver Diseases (AASLD) conference in Dallas, Texas October 26-29.Ribozymes are the product of Nobel Prize winning science and are synthetically engineered to act as "molecular scissors" capable of cleaving target RNA in a highly specific manner.Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs.RPI (www.rpi.com), located in Boulder, Colorado, is the acknowledged leader in ribozyme therapeutic development. In addition to its collaboration with Lilly for development of an anti-HCV ribozyme, RPI is partnered with Chiron Corporation for the development and commercialization of ANGIOZYME, an anti-angiogenic ribozyme designed to inhibit the growth of new blood supplies to tumors and prevent tumor growth and metastasis. ANGIOZYME is in Phase I/II clinical trials in cancer patients at the Cleveland Clinic. RPI is also partnered with an affiliate of Elan Corporation plc for development and commercialization of HERZYME, an anti-HER-2 ribozyme for treatment of breast and other cancers, through RPI's subsidiary Medizyme Pharmaceuticals Ltd.This press release contains forward-looking statements that involve risks and uncertainties, and actual events or results may differ materially. These risk factors include the outcome of future clinical trials, actions by the U.S. Food and Drug Administration, technological advances, ability to obtain rights to technology, ability to obtain and enforce patents, ability to commercialize and manufacture products and general economic conditions. These and additional risk factors are identified in RPI and Lilly Securities and Exchange Commission filings, including the Forms 10-K and 10-Q and in other SEC filings.SOURCE Ribozyme Pharmaceuticals, Inc. and Eli Lilly and Company VOTE For My List! Help us become No. 1.Check out which lists are the most POPULAR!Vote Now : <A HREF=" http://www.e4joy.com/cgi-bin/r.cgi?i=283 ">The ListDirectory</A>--- THE LIST DIRECTORY ----Jokes : Toons : Free Stuff : Motivation : InternetFind the Worlds most popular Mailing Lists:<A HREF=" http://www.e4joy.com/cgi-bin/r.cgi?i=283 ">The List Directory</A>

[Guest guest]

-----Original Message-----From: Demastus@... [mailto:Demastus@...]Sent: Monday, September 11, 2000 6:28 PMHepCegroupsSubject: [HepC] Anti-Hepatitis C Ribozyme Safety and Pharmacokinetics Trial Successfully Complet

Anti-Hepatitis C Ribozyme Safety and Pharmacokinetics Trial Successfully CompletedBOULDER, Colo. and INDIANAPOLIS, Sept. 11 /PRNewswire/ -- Ribozyme Pharmaceuticals, Inc. (RPI) (Nasdaq: RZYM) and Eli Lilly and Company (NYSE: LLY) announced today the successful completion of a safety and pharmacokinetic study of LY466700, the Anti-Hepatitis C ribozyme compound discovered by RPI.The trial was designed to examine safety and bioavailability in patients during a 28 day dosing regimen and was not designed to determine efficacy. Preliminary results indicate that the drug was very well tolerated over a 28 day period and that its pharmacokinetic characteristics support a subcutaneous dosing regimen, a mode of administration already familiar to chronic Hepatitis C patients."In contrast to currently available Hepatitis C therapies, this new class of therapeutics has shown an exceptional safety profile thus far," said Ralph E. Christoffersen, Ph.D., President and CEO of Ribozyme Pharmaceuticals. "We are pleased with the results of this study."Data from the most recent clinical trials will be discussed at the American Association for the Study of Liver Diseases (AASLD) conference in Dallas, Texas October 26-29.Ribozymes are the product of Nobel Prize winning science and are synthetically engineered to act as "molecular scissors" capable of cleaving target RNA in a highly specific manner.Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs.RPI (www.rpi.com), located in Boulder, Colorado, is the acknowledged leader in ribozyme therapeutic development. In addition to its collaboration with Lilly for development of an anti-HCV ribozyme, RPI is partnered with Chiron Corporation for the development and commercialization of ANGIOZYME, an anti-angiogenic ribozyme designed to inhibit the growth of new blood supplies to tumors and prevent tumor growth and metastasis. ANGIOZYME is in Phase I/II clinical trials in cancer patients at the Cleveland Clinic. RPI is also partnered with an affiliate of Elan Corporation plc for development and commercialization of HERZYME, an anti-HER-2 ribozyme for treatment of breast and other cancers, through RPI's subsidiary Medizyme Pharmaceuticals Ltd.This press release contains forward-looking statements that involve risks and uncertainties, and actual events or results may differ materially. These risk factors include the outcome of future clinical trials, actions by the U.S. Food and Drug Administration, technological advances, ability to obtain rights to technology, ability to obtain and enforce patents, ability to commercialize and manufacture products and general economic conditions. These and additional risk factors are identified in RPI and Lilly Securities and Exchange Commission filings, including the Forms 10-K and 10-Q and in other SEC filings.SOURCE Ribozyme Pharmaceuticals, Inc. and Eli Lilly and Company VOTE For My List! Help us become No. 1.Check out which lists are the most POPULAR!Vote Now : <A HREF=" http://www.e4joy.com/cgi-bin/r.cgi?i=283 ">The ListDirectory</A>--- THE LIST DIRECTORY ----Jokes : Toons : Free Stuff : Motivation : InternetFind the Worlds most popular Mailing Lists:<A HREF=" http://www.e4joy.com/cgi-bin/r.cgi?i=283 ">The List Directory</A>